Cargando…

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study

OBJECTIVES: To investigate the efficacy of vibegron on nocturia in patients with overactive bladder. METHODS: Among the Japanese overactive bladder patients enrolled in the placebo‐controlled, multicenter, randomized, double‐blind phase 3 study of vibegron, a total of 669 patients with nocturia (≥1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Masaki, Takeda, Masayuki, Gotoh, Momokazu, Yokoyama, Osamu, Kakizaki, Hidehiro, Takahashi, Satoru, Masumori, Naoya, Nagai, Shinji, Hashimoto, Keita, Minemura, Kazuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912249/ https://www.ncbi.nlm.nih.gov/pubmed/30557916 http://dx.doi.org/10.1111/iju.13877

Ejemplares similares

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study
por: Yoshida, Masaki, et al.
Publicado: (2022)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
por: Kwon, Taekmin, et al.
Publicado: (2017)

Comparison of the Uroflowmetry Parameter Results Between Transgender Males Undergoing Gender-Affirming Hormone Therapy and Age-Matched Cisgender Females: Preliminary Data
por: Matsuo, Kazuna, et al.
Publicado: (2019)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

Practical points in the medical treatment of overactive bladder and nocturia in the elderly
por: Chen, Jing-Liang, et al.
Publicado: (2016)

A watershed paper for surgical cure of overactive bladder and nocturia
por: Petros, Peter
Publicado: (2021)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
por: Yamaguchi, Osamu, et al.
Publicado: (2018)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Clinical Utility of β(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations
por: Krhut, Jan, et al.
Publicado: (2022)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Efficacy of mirabegron, a β(3)‐adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post‐hoc analysis of pooled data from two randomized, placebo‐controlled, double‐blind studies
por: Takahashi, Satoru, et al.
Publicado: (2021)

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
por: Weber, Michael A., et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
por: Masumori, Naoya
Publicado: (2013)

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
por: Shin, Jung Hyun, et al.
Publicado: (2023)

MRI Assessment of Cardiomyopathy Induced by β1-Adrenoreceptor Autoantibodies and Protection Through β3-Adrenoreceptor Overexpression
por: Vanhoutte, Laetitia, et al.
Publicado: (2017)

Testosterone Deficiency and Nocturia: A Review
por: Shigehara, Kazuyoshi, et al.
Publicado: (2017)

Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence
por: Lee, Sang Keun, et al.
Publicado: (2014)

Efficacy and safety of the noradrenaline reuptake inhibitor, TAS‐303, in women with stress urinary incontinence: Results of a double‐blind, randomized, placebo‐controlled, early phase II trial
por: Takahashi, Satoru, et al.
Publicado: (2020)

Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study
por: Katoh, Takao, et al.
Publicado: (2020)

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density
por: Yamamoto, Shota, et al.
Publicado: (2023)

Pharmacotherapy for Nocturia
por: Andersson, Karl-Erik, et al.
Publicado: (2018)

Spotlight on ROS and β3-Adrenoreceptors Fighting in Cancer Cells
por: Calvani, Maura, et al.
Publicado: (2019)

Effect of Beta 3 Adrenoreceptor Modulation on Patency of the Ductus Arteriosus
por: Pini, Alessandro, et al.
Publicado: (2020)

Effects of fatty acid metabolites on nocturia
por: Ihara, Tatsuya, et al.
Publicado: (2022)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

ß-Adrenoreceptors in Human Cancers
por: Kraboth, Zoltan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sea4v75gfoa68im491d170vivu